This year's ViVE conference featured a variety of news announcements — from company launches to new products to partnerships to acquisitions and more. In this list, MedCity News compiled short summaries for nine of the conference's most notable announcements.
Check out news from Alpha Sophia, Abridge, Baseimmune, Carewell, and Redi Health.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Regenerative medicine startup Pelage Pharmaceuticals has clinical data showing its small molecule activated hair follicle stem cells. GV led a Series A round that funded the UCLA spinout’s Phase 1 clinical trial and will also support Phase 2 testing this year.
In the venture capital community, there’s a bit of a debate about what matters more to digital health investors in today's fundraising environment — growth or profitability. Cathy Gao, a partner at Sapphire Ventures, thinks VCs are still putting a premium on growth, but she noted that the conversation is very nuanced.
Vale Health announced its launch on Monday at ViVE. The startup's platform helps health systems connect their patients to health and wellness products, which are becoming increasingly interesting to consumers. Vale has 16 founding health systems partners that will go live with the platform, with the Froedtert & the Medical College of Wisconsin health network being the first.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.
The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!
About 80% of all FDA-approved healthcare AI applications are related to radiology — but due to a massive workforce shortage, radiologists don't have the time to explore, choose, validate and implement the tools available to them. Some providers are using a radiology AI marketplace called CARPL to address this problem, including Massachusetts General Hospital and University Hospitals.
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
HealthSnap closed a $25 million Series B funding round led by Sands Capital. The Miami-based company seeks to help providers better care for a rapidly aging and chronically ill population through its remote patient monitoring platform.
The conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, is the premier boutique healthcare investment event in the U.S.
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
Versant Ventures-backed Firefly Bio is part of a growing group of companies developing degrader antibody conjugates, or DACs. These targeted cancer therapies combine properties of antibody drug conjugates and protein degraders in order to overcome limitations of both types of therapies.
Headlight's funding round was led by Matrix and EPIC Ventures. The company also hired new leadership, including CEO Geoff Swindle, who was formerly chief business officer at PillPack and Amazon Pharmacy.